Payment overview · 2025
General Payments
$479.78
36 reported records · 5 companies
Healthcare provider profile · identity verified
Benjamin J Cochran, APRN, DNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ALTAMONT, KS · NPI 1912339672
Verified facts
What the public records show
CMS Open Payments records show Benjamin J Cochran, APRN, DNP received $479.78 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 54.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $262.25 | 54.7% | 23 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $102.69 | 21.4% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $79.75 | 16.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.66 | 3.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.43 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $479.78 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $210.51 | 20 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $102.69 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $79.75 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.74 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 279 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 235 | 48 |
| Omeprazole | Omeprazole | 230 | 41 |
| Furosemide | Furosemide | 222 | 46 |
| Lisinopril | Lisinopril | 221 | 55 |
| Alprazolam | Alprazolam | 214 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 212 | 44 |
| Gabapentin | Gabapentin | 208 | 37 |
| Metformin Hcl | Metformin Hcl | 206 | 35 |
| Potassium Chloride | Potassium Chloride | 204 | 42 |
| Montelukast Sodium | Montelukast Sodium | 201 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 32 |
| Meloxicam | Meloxicam | 172 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 152 | 12 |
| Losartan Potassium | Losartan Potassium | 144 | 34 |
| Tramadol Hcl | Tramadol Hcl | 121 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 26 |
| Lovastatin | Lovastatin | 101 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 26 |
| Eliquis | Apixaban | 90 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 18 |
| Mounjaro | Tirzepatide | 80 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 12 |
| Trazodone Hcl | Trazodone Hcl | 78 | suppressed |
| Prednisone | Prednisone | 72 | 37 |
| Simvastatin | Simvastatin | 72 | 15 |
| Atenolol | Atenolol | 68 | 11 |
| Baclofen | Baclofen | 68 | 22 |
| Propranolol Hcl | Propranolol Hcl | 68 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 67 | 17 |
| Sertraline Hcl | Sertraline Hcl | 66 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 66 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 16 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | suppressed |
| Gemfibrozil | Gemfibrozil | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 14 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 58 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 57 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 11 |
| Pregabalin | Pregabalin | 54 | 11 |
| Famotidine | Famotidine | 53 | 11 |
| Allopurinol | Allopurinol | 52 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Carvedilol | Carvedilol | 44 | 18 |
| Clindamycin Hcl | Clindamycin Hcl | 44 | 36 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 28 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 11 |
| Prempro | Estrogen,con/M-Progest Acet | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 22 |
| Azithromycin | Azithromycin | 35 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Lidocaine | Lidocaine | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 22 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 11 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 21 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $479.78 · 36 records | ABBVIE INC. | AIRSUPRA, CAPLYTA, FANAPT, HETLIOZ, QULIPTA, REXULTI, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error